Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic Co-Authors Study Published in International Peer-Reviewed Journal Aesthetic Plastic Surgery
Systematic Review Validates Effectiveness and Safety of Radiofrequency Microneedling Across a Broad Range of Dermatological Conditions
IRVINE, Calif. — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced that Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic — a clinic network under SBC Medical's management support — has co-authored a study published in Aesthetic Plastic Surgery, an international peer-reviewed journal published by Springer and the official journal of the International Society of Aesthetic Plastic Surgery (ISAPS).
The paper, titled "Effectiveness of Radiofrequency Microneedling in the Treatment of Dermatological Conditions: A Systematic Review," comprehensively analyzes clinical research from around the world to evaluate the efficacy and safety of radiofrequency microneedling (RFMN), an increasingly utilized aesthetic healthcare technology. The findings highlight RFMN's potential as an effective treatment option for a wide range of skin concerns, including acne scarring, skin laxity, and wrinkles.
● Background and Significance of the Research
Radiofrequency microneedling is a minimally invasive procedure that combines fine needles with high-frequency energy to stimulate collagen production in the deeper layers of the skin. The technique has gained widespread adoption both domestically and internationally for its ability to improve skin quality with minimal downtime. However, prior to this study, research had largely been segmented by individual condition, with limited data offering a cross-condition evaluation of its effectiveness.
● Key Findings
This systematic review analyzed multiple clinical studies published over approximately the past decade to provide a comprehensive assessment of RFMN's efficacy and safety. Key findings include:
For acne scarring, RFMN demonstrated improvement outcomes comparable to conventional treatments, with the added advantages of faster recovery and a favorable side effect profile. The review also confirmed improvements in skin laxity and wrinkles, suggesting broad clinical applicability. From a safety standpoint, adverse reactions were predominantly mild and transient — such as temporary redness — with no serious complications reported, and overall customer satisfaction remained at a high level.
● Advancing Academic Collaboration in Aesthetic Healthcare
Technological innovation in aesthetic healthcare continues to accelerate, bringing with it a growing need not only for clinical excellence but also for the sharing of specialized knowledge and academic collaboration. Addressing increasingly diverse customer needs requires the integration of cutting-edge technologies alongside broad perspectives and flexible thinking. SBC Medical Group is committed to advancing its academic activities and fostering engagement with research institutions, with the goal of continuously enhancing the safety, transparency, and long-term value of aesthetic healthcare.
● Publication Details
Journal: Aesthetic Plastic Surgery (Springer; Official Journal of ISAPS)
Paper Title: Effectiveness of Radiofrequency Microneedling in the Treatment of Dermatological Conditions: A Systematic Review
Authors: Narendra Kumar, Hyoung Moon Kim, Ayaka Nishikawa, Chan Yeong Heo, Woffles T. L. Wu
URL: https://link.springer.com/article/10.1007/s00266-026-05834-y
About Dr. Ayaka Nishikawa
After graduating from the School of Medicine at Yokohama City University, Dr. Ayaka Nishikawa joined Shonan Beauty Clinic in 2015 as a dermatologist specializing in aesthetic medicine. In 2018, she was appointed Chief Director of Dermatology and currently oversees a wide range of initiatives across the SBC Medical Group, including the development of new dermatological treatments, technical training for doctors and nurses, and safety management. Through the analysis of clinical cases, she is dedicated to promoting evidence-based medical practice and actively engages in academic activities such as presenting at domestic and international conferences and contributing to medical journals. In recognition of her achievements, she was appointed Visiting Professor at SBC Tokyo Medical University in 2023. For more information on Dr. Nishikawa’s professional profile, please visit [here].
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp